Eli Lilly and Company  and Nexus Pharmaceuticals, today announced a definitive agreement for Lilly to acquire a manufacturing facility from Nexus, a leading sterile manufacturer in the pharmaceutical industry. “The acquisition of this state-of-the-art facility underscores our...

Anglo-Swedish drugmaker AstraZeneca  on Wednesday announced the global withdrawal of its Covid-19 vaccine Vaxzevria. Demand for AstraZeneca’s Vaxzevria vaccine began tapering off as new vaccines tailored to specific Covid variants have emerged, the pharmaceutical company said in a...

US multinational pharmaceutical company Bristol Myers Squibb is to acquire radiological drug developer RayzeBio, Inc. for approximately $4.1bn. Bristol Myers Squibb will acquire RayzeBio for $62.50 per share in cash, representing a premium of 104 percent to the stock’s last close....

AstraZeneca had announced the successful completion of the acquisition of Icosavax, Inc., a US-based clinical-stage biopharmaceutical company focused on developing differentiated, high-potential vaccines using an innovative, protein virus-like particle (VLP) platform. As a result of...

Gilead has agreed to acquire CymaBay, a Newark, California-based clinical-stage bio/pharmaceutical company, for $4.3 billion. CymaBay’s lead candidate is seladelpar, an oral drug for treating primary biliary cholangitis (PBC), a rare, chronic, cholestatic liver disease. Under the...

Kyowa Kirin has agreed to acquire gene therapy developer Orchard Therapeutics for up to $477.6 million, to develop several biopharmaceutical candidates in areas including oncology and autoimmune diseases. Under the terms of the agreement, Kyowa will acquire Orchard for $16 per...

    Sanofi has agreed to buy US biotech firm Inhibrx in a deal valued at up to $2.2bn, bolstering its drug development portfolio with an experimental treatment for a rare genetic disease. Under the terms of the agreement, Sanofi will acquire all outstanding shares of...

    Bora Pharmaceuticals, a contract development and manufacturing organization (CDMO), has officially acquired Upsher-Smith Laboratories, a specialty-brand and generics company, for $210 million. Upsher-Smith, founded in 1919 and owned by Sawai since 2017, has a...

    GSK’s acquisition, which comes amid other big money moves in the pharma industry, aims to broaden its asthma drug range. GSK’s acquisition will give the company access to Aiolos’ AIO-001, a monoclonal antibody that is ready to start Phase II trials for the treatment of...

  Zevra has obtained access to Acer’s rare disease assets Olpruva and Edsivo. Zevra Therapeutics has concluded its takeover of complete outstanding shares of Acer Therapeutics to form a rare disease company in a $91m deal. Zevra has obtained access to Acer’s rare...